Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
US-12163168-B2 · Dec 10, 2024 · US
This page is not indexed by search engines while we improve data quality.
Stone Everett patents
Stone Everett is listed as an inventor on 53 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Stone Everett |
| Total patents | 53 |
| First publication | Mar 5, 2015 |
| Latest publication | Dec 10, 2024 |
Notable patents
Publications ranked by popularity score, then publication date.
Human Kynureninase enzymes and uses thereof
US-12144828-B2 · Nov 19, 2024 · US
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
US-12036269-B2 · Jul 16, 2024 · US
Administration of kynurenine depleting enzymes for tumor therapy
US-2024091258-A1 · Mar 21, 2024 · US
Novel nicotine degrading enzyme variants
US-2023416697-A1 · Dec 28, 2023 · US
Human kynureninase enzymes and uses thereof
US-2023405049-A1 · Dec 21, 2023 · US
Enzyme-mediated depletion of adenosine and/or methylthioadenosine
US-2023227796-A1 · Jul 20, 2023 · US
Human kynureninase enzymes and uses thereof
US-11648272-B2 · May 16, 2023 · US
Nicotine degrading enzyme variants
US-11597916-B2 · Mar 7, 2023 · US
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
US-11591579-B2 · Feb 28, 2023 · US
Recent patents
Latest publications not already listed above.
Human kynureninase enzyme variants having improved pharmacological properties
US-11542486-B2 · Jan 3, 2023 · US
Nucleic acids encoding kynurenine depleting enzymes
US-11534463-B2 · Dec 27, 2022 · US
Administration of kynurenine depleting enzymes for tumor therapy
US-2022275099-A1 · Sep 1, 2022 · US
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
US-11426464-B2 · Aug 30, 2022 · US
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
US-11396647-B2 · Jul 26, 2022 · US
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
US-2022047683-A1 · Feb 17, 2022 · US
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
US-2022042001-A1 · Feb 10, 2022 · US
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
US-2021386838-A1 · Dec 16, 2021 · US
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
US-2021380962-A1 · Dec 9, 2021 · US
Administration of kynurenine depleting enzymes for tumor therapy
US-11168142-B2 · Nov 9, 2021 · US
Enzyme-mediated depletion of adenosine and/or methylthioadenosine
US-11118167-B2 · Sep 14, 2021 · US
Administration of kynurenine depleting enzymes for tumor therapy
US-2021213059-A1 · Jul 15, 2021 · US
Human kynureninase enzyme variants having improved pharmacological properties
US-2021207110-A1 · Jul 8, 2021 · US
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
US-11033612-B2 · Jun 15, 2021 · US
Enzyme-mediated depletion of adenosine and/or methylthioadenosine
US-2021095264-A1 · Apr 1, 2021 · US
Enzyme-mediated depletion of adenosine and/or methylthioadenosine
US-2021054350-A1 · Feb 25, 2021 · US
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
US-10865403-B2 · Dec 15, 2020 · US
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
US-2020338197-A1 · Oct 29, 2020 · US
Administration of kynurenine depleting enzymes for tumor therapy
US-10772913-B2 · Sep 15, 2020 · US
Engineered primate L-methioninase for therapeutic purposes
US-10724026-B2 · Jul 28, 2020 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Univ Texas | 53 |
| Antidote Therapeutics Inc | 3 |
Top CPC classifications
Most common classification codes across this inventor's patents.